Avycaz (Ceftazidime/Avibactam) Patent Expiration, LOE Window & CMS Spending

Avycaz (Ceftazidime/Avibactam) by AbbVie: FDA Orange Book core substance LOE 2032-06-15, 0 AB generics, $27.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN206494 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-06-15
Last Listed Patent or Exclusivity Date2032-06-15
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$27.5M
2024 Medicare Part D Spend$19.5M
2024 Medicaid Spend$7.9M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 18.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.